Author

L. Reynoso

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 3 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 2 Organism:virus· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1

Frequent Co-Authors

G. Downey· 3 shared G. Zhang· 3 shared H. Liu· 3 shared K. Aviszus· 3 shared P. Marrack· 3 shared P. Wei· 3 shared Q. Zhang· 3 shared S. Frankel· 3 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

G. Downey

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Simultaneous detection of pathogens and antimicrobial resistance genes with the open source, cloud-based, CZ ID pipeline

D. Lu, K. L. Kalantar, V. T. Chu, A. L. Glascock, E. S. Guerrero, N. Bernick, X. Butcher, K. Ewing, E. Fahsbender, O. Holmes, E. Hoops, A. E. Jones, R. Lim, S. McCanny, L. Reynoso, , C. R. Langelier

The paper develops an open-source, cloud-based tool for detecting pathogens and antimicrobial resistance genes in metagenomic and whole-genome sequencing data, demonstrating its application across clinical and environmental studies.

bioRxiv · Apr 12, 2024 · PreprintMicrobiology

The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines

H. Liu, P. Wei, Q. Zhang, K. Aviszus, J. Linderberger, J. Yang, J. Liu, Z. Chen, H. Waheed, L. Reynoso, G. Downey, S. Frankel, J. Kappler, P. Marrack, G. Zhang

The paper compares vaccine efficacy against Delta and Lambda SARS-CoV-2 variants, finding Lambda has greater escape potential, with reduced antibody reactivity and therapeutic antibody binding.

bioRxiv · Aug 25, 2021 · PreprintImmunology

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro

H. Liu, P. Wei, Q. Zhang, Z. Chen, K. Aviszus, W. Downing, S. Peterson, L. Reynoso, G. Downey, S. Frankel, J. Kappler, P. Marrack, G. Zhang

The paper shows that the 501Y.V2 and 501Y.V3 SARS-CoV-2 variants have mutations that reduce binding to the antibody Bamlanivimab.

bioRxiv · Feb 16, 2021Biochemistry

The basis of a more contagious 501Y.V1 variant of SARS-COV-2

G. Zhang, H. Liu, Q. Zhang, P. Wei, Z. Chen, K. Aviszus, J. Yang, W. Downing, S. Peterson, C. Jiang, B. Liang, L. Reynoso, G. Downey, S. Frankel, J. Kapper, P. Marrack

This paper investigates the increased transmissibility of the SARS-CoV-2 501Y.V1 variant due to the N501Y mutation in the Spike protein's RBD and its impact on ACE2 binding and vaccine efficacy.

bioRxiv · Feb 2, 2021Biochemistry